Literature DB >> 26582440

Long-term Sequelae of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Che-Wen Yang1, Yung-Tsu Cho, Kai-Lung Chen, Yi-Chun Chen, Hsiang-Lin Song, Chia-Yu Chu.   

Abstract

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe cutaneous adverse drug reactions characterized by different extents of epidermal necrosis and mucosal breakdown. A limited number of studies have reported the long-term patterns of SJS and TEN complications in patient populations over long follow-up periods. The aim of this retrospective study was to collect data on long-term sequelae in patients admitted for SJS, SJS/TEN overlap, or TEN between 1998 and 2012. Among all 102 patients eligible for analysis, the 2 most common sequelae were cutaneous and ocular problems, both with incidences of 44.1%. Visceral organ involvement was observed in 2 patients with irreversible deterioration of chronic kidney disease and in one patient with interstitial lung disease. Autoimmune disease was present in 6 patients: Sjögren's syndrome or Sjögren-like syndrome in 5 patients and concomitant systemic lupus erythematosus and Hashimoto thyroiditis in one patient.

Entities:  

Mesh:

Year:  2016        PMID: 26582440     DOI: 10.2340/00015555-2295

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN: 0001-5555            Impact factor:   4.437


  22 in total

1.  Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.

Authors:  Eric P Borrelli; Erica Y Lee; Andrew M Descoteaux; Stephen J Kogut; Aisling R Caffrey
Journal:  Epilepsia       Date:  2018-11-05       Impact factor: 5.864

2.  Is universal HLA-B*15:02 screening a cost-effective option in an ethnically diverse population? A case study of Malaysia.

Authors:  H Y Chong; Z Mohamed; L L Tan; D B C Wu; F H Shabaruddin; M Dahlui; Y D Apalasamy; S R Snyder; M S Williams; J Hao; L H Cavallari; N Chaiyakunapruk
Journal:  Br J Dermatol       Date:  2017-09-21       Impact factor: 9.302

Review 3.  [Severe cutaneous drug reactions in children].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2017-10       Impact factor: 0.751

Review 4.  [Acute life-threatening drug reactions of the skin].

Authors:  M Mockenhaupt
Journal:  Hautarzt       Date:  2018-05       Impact factor: 0.751

5.  Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Swapna S Shanbhag; Leangelo Hall; James Chodosh; Hajirah N Saeed
Journal:  Ocul Surf       Date:  2020-03-19       Impact factor: 5.033

6.  Chronic pulmonary complications associated with toxic epidermal necrolysis: A case report and literature review.

Authors:  Nuo Xu; Xuehua Chen; Shengdi Wu; Maosong Ye; Meiling Zhang; Lin Tong; Xiaodan Zhu; Jie Liu; Feifei Hu; Chunxue Bai
Journal:  Exp Ther Med       Date:  2018-06-27       Impact factor: 2.447

7.  Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.

Authors:  Bénédicte Lebrun-Vignes; Claire Guy; Marie-Josèphe Jean-Pastor; Valérie Gras-Champel; Marie Zenut
Journal:  Br J Clin Pharmacol       Date:  2017-11-10       Impact factor: 4.335

Review 8.  Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances.

Authors:  Teresa Bellón
Journal:  Drug Saf       Date:  2019-08       Impact factor: 5.228

Review 9.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

Review 10.  Lamotrigine and Stevens-Johnson Syndrome Prevention.

Authors:  Amber N Edinoff; Long H Nguyen; Mary Jo Fitz-Gerald; Erin Crane; Kyle Lewis; Samantha St Pierre; Alan D Kaye; Adam M Kaye; Jessica S Kaye; Rachel J Kaye; Sonja A Gennuso; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Psychopharmacol Bull       Date:  2021-03-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.